This is a working overview of AOD9604, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-17. Anything still debated is marked as such rather than presented as settled.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
Laboratory studies have reported that AOD9604 can increase lipolysis and reduce lipid accumulation in fat cells. The precise molecular target remains uncertain, and the compound does not appear to activate the growth hormone receptor in the same way as full-length hGH. Proposed mechanisms include effects on beta-adrenergic signaling and enzymes involved in fatty acid synthesis, but these pathways are not firmly established. Because most evidence comes from cell and animal models, whether the same effects occur in humans is an open question.
Clinical development of AOD9604 included trials in people with obesity, but the results did not lead to approval as a prescription medicine in major markets. Interest later shifted to research settings and to unapproved products marketed for body composition. Regulatory agencies have questioned whether the peptide qualifies as a dietary ingredient, and some have issued warnings about its presence in supplements. Long-term human safety data are limited, and questions about efficacy, dosing, and target populations remain unresolved.
AOD9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to a short sequence near the end of the 191-amino-acid hormone, often described as residues 176–191 or a related fragment. Researchers designed it to separate metabolic effects from the growth-promoting actions of full-length growth hormone. Early work in the 1990s explored it as a candidate for weight and lipid disorders. It is not a naturally circulating hormone fragment produced in large amounts.
The "Neanderthaloids" of Africa and East Asia were reclassified as distant relatives to H. neanderthalensis. At around the same time, the "Out of Asia" hypothesis was overturned by the "Out of Africa" hypothesis, which posited that all modern humans share a fully modern common ancestor (monogenism). There were two main schools of thought: modern humans competitively replaced all other archaic humans ("Replacement"), or extensively interbred with them while dispersing throughout the world ("Regional Continuity"). In 2010, the first mapping of the Neanderthal genome demonstrated that there was at least some interbreeding between archaic and modern humans. Subsequent genetic studies continue to raise questions on how Neanderthals should be classified relative to modern humans.
=== Founding === Five Guys was founded in 1986 by Janie and Jerry Murrell. Jerry and the couple's sons Jim, Matt, Chad, and Ben were the original "Five Guys". The Murrells had a fifth son, Tyler, two years later. Today, all five sons, the current "Five Guys", are involved in the business: Matt and Jim travel the United States visiting stores, Chad oversees training, Ben selects the franchisees, and Tyler runs the bakery. The first Five Guys was in Arlington's Westmont Shopping Center. Buns were baked in the same center by Brenner's Bakery. This location closed, in favor of another in Alexandria, Virginia, at the intersection of King and North Beauregard Streets, which closed on September 21, 2013.
This results in rhinorrhea, itchiness, dyspnea, and anaphylaxis. Depending on the individual, allergen, and mode of introduction, the symptoms can be system-wide (classical anaphylaxis) or localized to specific body systems. Asthma is localized to the respiratory system, and eczema is localized to the dermis.
Most of the isotopes of each chemical element present in the Earth today were formed by such processes no later than the time of our planet's condensation from the solar protoplanetary disc, around 4.5 billion years ago. The exceptions to these so-called primordial elements are those that have resulted from the radioactive disintegration of unstable parent nuclei as they progress down one of several decay chains, each of which terminates with the production of one of the 251 stable isotopes known to exist. Aside from cosmic or stellar nucleosynthesis, and decay chains the only other ways of producing a chemical element rely on atomic weapons, nuclear reactors (natural or manmade) or the laborious atom-by-atom assembly of nuclei with particle accelerators. Unstable isotopes decay to their daughter products (which may sometimes be even more unstable) at a given rate; eventually, often after a series of decays, a stable isotope is reached: there are 251 stable isotopes in the universe. In stable isotopes, light elements typically have a lower ratio of neutrons to protons in their nucleus than heavier elements. Light elements such as helium-4 have close to a 1:1 neutron:proton ratio. The heaviest elements such as uranium have close to 1.5 neutrons per proton (e.g. 1.587 in uranium-238). No nuclide heavier than lead-208 is stable; these heavier elements have to shed mass to achieve stability, mostly by alpha decay.
== Signal transduction pathway == A glucagon receptor, upon binding with the signaling molecule glucagon, initiates a signal transduction pathway that begins with the activation of adenylate cyclase, which in turn produces cyclic AMP (cAMP). Protein kinase A, whose activation is dependent on the increased levels of cAMP, is responsible for the ensuing cellular response in the form of protein kinase 1 and 2. The ligand-bound glucagon receptor can also initiate a concurrent signaling pathway that is independent of cAMP by activating phospholipase C. Phospholipase C produces DAG and IP3 from PIP2, a phospholipid phospholipase C cleaves off of the plasma membrane. Ca2+ stores inside the cell release Ca2+ when its calcium channels are bound by IP3.
Sources: en.wikipedia.org
=== Buses === Bromley is served by London Buses routes 61, 119, 126, 138, 146, 162, 208, 227, 246, 261, 269, 314, 320, 336, 352, 354, 358, 367, 638, N3, N199, SL3 and SL5. These connect it with areas including Beckenham, Bexley, Bexleyheath, Biggin Hill, Catford, Chislehurst, Croydon, Crystal Palace, Downham, Elmers End, Eltham, Grove Park, Hayes, Lee Green, Lewisham, Locksbottom, Mottingham, New Addington, Orpington, Penge, Petts Wood, Sidcup, West Wickham & Westerham.
=== Anthropogenic influences === Anthropogenic industry unintentionally injects micronutrients into various ecosystems across the globe. The addition of micronutrients into ecosystems can have both positive and negative impacts. In the face of climate change, the fertilization of oceans with iron has been proposed as a method of carbon sequestration; however, elevated levels of iron in high nutrient, low chlorophyll regions of the ocean can cause the production of harmful algal blooms which are toxic to both humans and marine life. Similarly, in lakes, isolated seas, and coastal bays or gulfs, addition of micronutrients can cause eutrophication leading to hypoxia, decreasing ecosystem health. Micronutrients are released into ecosystems from many anthropogenic activities. Fossil fuel combustion releases micronutrients such as Zn, Fe, Ni, and Cu into the atmosphere, surrounding soils, and nearby waterways. Agricultural fertilizer runoff contains many micronutrients like Fe, Mn, Zn, Cu, Co, B, Mo and Ni. Fertilizer runoff injects these micronutrients into groundwater, soils, and waterways. Deforestation decreases soil compaction, resulting in increased aeolian transport of dust containing micronutrients, especially Fe. Industrial mining produces tailings which contaminates runoff. The improper treatment of mining tailings can result in the leakage of micronutrients into groundwater, soils, and nearby waterways.
== Clinical trials == Innovation Pharmaceuticals advanced brilacidin through early stage human clinical trials to a completed Phase 2a proof-of-concept clinical trial. Since acquisition, brilacidin was entered into a Phase 2b clinical trial. Brilacidin was granted the Qualified Infectious Disease Product (QIDP) designation by the FDA under the Generating Antibiotic Incentives Now Act of 2011 (GAIN Act).
The circulatory system is a system of organs that includes the heart, blood vessels, and blood which is circulated throughout the body. It includes the cardiovascular system, which consists of the heart and blood vessels. Some sources use the terms cardiovascular system, vascular system and circulatory system interchangeably. The lymphatic system (comprising lymphatic vessels, lymph nodes, lymphoid organs, lymphatic tissue and lymph) is complementary to the circulatory system and forms part of the immune system.
The ancient Indian sexual treatise Kama Sutra, written in Sanskrit, probably between the second and fourth centuries AD, divides men into three classes based on penis size: "hare" size (about 5–7 cm, or 2–3 inches, when erect), "bull" size (10–15 cm, or 4–6 inches), and "horse" size (18–20 cm, or 7–8 inches). The treatise also divides women's vaginas into three sizes ("deer", "mare", and "elephant") and advises that a man match the size of the vagina of the woman he is having sex with to the size of his own penis. It also gives medically dubious advice on how to enlarge one's penis using wasp stings.
Sources: en.wikipedia.org
Indolyl-3-acryloylglycine, also known as trans-indolyl-3-acryloylglycine, or IAG for short, is a compound consisting of an indole group attached to an acrylic acid moiety, which is in turn attached to a glycine molecule. This compound has been shown to isomerize when exposed to light. It is likely a metabolic intermediate in the biosynthesis of tryptophan, and is synthesized from tryptophan via indolepropionic acid and indoleacrylicacid (IAcrA). It is also likely that IAcrA is converted into IAG in the gut wall. It may also be produced by certain elements of the mammalian gut microbiota by phenylalanine ammonia-lyase. Identifiable in the urine by high-performance liquid chromatography, it may be a biomarker for autism spectrum disorders, as demonstrated by the research of Paul Shattock and other researchers from Australia. These researchers have reported that urinary levels of IAG are much higher in autistic children than in controls; however, other researchers have found no association between IAG concentrations in the urine and autism. Its excretion in the urine may also be changed in Hartnup disease and celiac disease, as well as photodermatosis, muscular dystrophy, and liver cirrhosis.
Histologically, an excess amount of keratin is noted on the surface of the tissue, and the tissue has all the layers of an orthokeratinized tissue with its granular and keratin layers. In patients who have habits such as clenching or grinding (bruxism) their teeth, a larger area of the buccal mucosa than just the linea alba becomes hyperkeratinized. This larger white, rough, raised lesion needs to be recorded so that changes may be made in the dental treatment plan regarding the patient's parafunctional habits. Even keratinized tissue can undergo further level of hyperkeratinization; an increase in the amount of keratin is produced as a result of chronic physical trauma to the region. Changes such as hyperkeratinization are reversible if the source of the injury is removed, but it takes time for the keratin to be shed or lost by the tissue. Thus, to check for malignant changes, a baseline biopsy and microscopic study of any whitened tissue may be indicated, especially if in a high-risk cancer category, such with a history of tobacco or alcohol use or are HPV positive. Hyperkeratinized tissue is also associated with the heat from smoking or hot fluids on the hard palate in the form of nicotinic stomatitis. The lamina propria is a fibrous connective tissue layer that consists of a network of type I and III collagen and elastin fibers in some regions. The main cells of the lamina propria are the fibroblasts, which are responsible for the production of the fibers as well as the extracellular matrix.
=== Concentration quotients === In aqueous solution, equilibrium constants are usually determined in the presence of an "inert" electrolyte such as sodium nitrate, NaNO3, or potassium perchlorate, KClO4. The ionic strength of a solution is given by
=== Behavioral evidence === Fossils of the troodonts Mei and Sinornithoides demonstrate that some dinosaurs slept with their heads tucked under their arms. This behavior, which may have helped to keep the head warm, is also characteristic of modern birds. Several deinonychosaur and oviraptorosaur specimens have also been found preserved on top of their nests, likely brooding in a bird-like manner. The ratio between egg volume and body mass of adults among these dinosaurs suggest that the eggs were primarily brooded by the male and that the young were highly precocial, similar to many modern ground-dwelling birds. Some dinosaurs are known to have used gizzard stones like modern birds. These stones are swallowed by animals to aid digestion and break down food and hard fibers once they enter the stomach. When found in association with fossils, gizzard stones are called gastroliths.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.